Detection of HBsAg and serotypes in blood plasma of HBV-positive individuals in Mongolia
DOI:
https://doi.org/10.5564/pib.v39i2.3324Keywords:
serotype, antibody titer, prototypeAbstract
Mongolia has the highest liver cancer incidence in the world, primarily attributed to hepatitis virus infections and the prevalence of liver diseases. The predominant focus in existing studies involved the detection of virus infections, and immunization against HBV, with HBsAg serving as a primary marker. In this study, blood donation samples were evaluated, which were positive for HBV and negative for HCV, HAV, HIV, and syphilis by ELISA test at the National Center for Transfusion Medicine (NCTM) of Mongolia. Furthermore, titer determination was performed by reverse passive hemagglutination (PHA) assay, and the antigen serotype was identified on an isolated HBsAg. Our result showed that, among 83 HBV-positive blood plasmas, 10 exhibited a high HBsAg titer, and the serotypes ayr and ayw were identified. The samples were categorized into groups A and B, and to analyze HBsAg reliability, the prototype models were assembled using HBsAg isolated from the high antigen yield group (A). As a result, the prototype models were stable in 3 months, but the sensitivity and specificity of the antigen were weaker compared to its standard.
Хепатитийн B вирус (HBV)-ийн халдвартай хүний цуснаас HBsAg ялган, серотипийг тодорхойлсон дүн
Хураангуй. Монгол улсын хүн амын дундах хепатитийн вирусийн халдвар болон вирусийн шалтгаант элэгний өвчлөлийн тохиолдол дэлхийд тэргүүлэх байранд байдаг. Олон улсад хепатитийн B вирус (HBV)-ийн оношилгоо болон дархлаажуулалтын судалгаанд гадаргуугийн эсрэгтөрөгч (HBsAg)-ийг өргөнөөр ашигладаг. Бид манай Цус сэлбэлт судлалын үндэсний төв (ЦССҮТ)-д цуглуулсан HBV-ийн халдвартай 83 донорын цусны ийлдэс дэх HBsAg-ийн илэрцийг тогтоон, эсрэгтөрөгчийн илэрц өндөр 10 дээжийг А болон Б бүлэгт ангилан HBsAg-ийг ялгаж, тус бүрд ayr болон ayw серотипүүдийг тодорхойлсон. Улмаар эсрэгтөрөгчийн агууламж өндөр А бүлгээс ялган авсан бөмбөлөг ба утаслаг эсрэгтөрөгчийг ашиглан прототип загварыг гарган авч шинж чанарыг тодорхойлоход тэдгээрийн тогтвортой байдал сайн хэдий ч мэдрэг болон өвөрмөц чанар нь стандарт эсрэгтөрөгчтэй харьцуулахад сул болохыг тогтоов. Энэ нь бидний судалгаагаар ayr болон ayw серотип бүхий эсрэгтөрөгч илэрсэнтэй хамааралтай байх боломжтой.
Түлхүүр үгс: серотип, эсрэгбиеийн таньц, прототип загвар
Downloads
100
References
H. Rumgay et al., “Global burden of primary liver cancer in 2020 and predictions to 2040,” J. Hepatol., vol. 77, no. 6, pp. 1598–1606, Dec. 2022, https://doi.org/10.1016/j.jhep.2022.08.021
O. Baatarkhuu, T. Gerelchimeg, D. Munkh-Orshikh, B. Batsukh, G. Sarangua, and J. Amarsanaa, “Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia,” Euroasian J. Hepato-Gastroenterology, vol. 8, no. 1, pp. 57–62, Jun. 2018, https://doi.org/10.5005/jp-journals-10018-1260.
Chronic Hepatitis B (Handbook for clinician). Asian liver center at Stanford University School of Medicine, 2020.
S. Sabeena and N. Ravishankar, “Horizontal Modes of Transmission of Hepatitis B Virus (HBV): A Systematic Review and Meta-Analysis,” Iran. J. Public Health, Oct. 2022, https://doi.org/10.18502/ijph.v51i10.10977.
W. H. Organization, “Hepatitis B,” 2023.
J. Pattyn, G. Hendrickx, A. Vorsters, and P. Van Damme, “Hepatitis B Vaccines,” J. Infect. Dis., vol. 224, no. Supplement_4, pp. S343–S351, Sep. 2021, https://doi.org/10.1093/infdis/jiaa668.
Paul A. Offit, K. M. Edwards, and S. A. Plotkin, Plotkin’s Vaccines, 7th edition. Elsevier, 2017.
G. L. Le Bouvier, “Subtypes of Australia antigen and hepatitis-B virus,” JAMA J. Am. Med. Assoc., vol. 222, no. 8, pp. 928–930, Nov. 1972, https://doi.org/10.1001/jama.222.8.928.
C. L. Lin and J. H. Kao, “Hepatitis B Virus Genotypes and Variants,” Cold Spring Harb. Perspect. Med., vol. 5, no. 5, pp. a021436–a021436, May 2015, https://doi.org/10.1101/cshperspect.a021436.
B. J. McMahon, “The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B,” Hepatol. Int., vol. 3, no. 2, pp. 334–342, Jun. 2009, https://doi.org/10.1007/s12072-008-9112-z.
S. Chevaliez, F. Roudot-Thoraval, C. Hézode, J.-M. Pawlotsky, and R. Njouom, “Performance of rapid diagnostic tests for hepatitis B surface antigen detection in serum or plasma,” Diagn. Microbiol. Infect. Dis., vol. 100, no. 2, p. 115353, Jun. 2021, https://doi.org/10.1016/j.diagmicrobio.2021.115353.
M. C. Els, M. Govender, T. Marimuthu, M. O. Bubb, and J. D. Conradie, “Mouse Monoclonal Anti‐HBs and Its Use in the Screening of Donated Blood by Elisa,” Vox Sang., vol. 46, no. 3, pp. 165–174, Mar. 1984, https://doi.org/10.1111/j.1423-0410.1984.tb00070.x.
H. Momose et al., “Performance evaluation of in vitro diagnostic kits for hepatitis B virus infection using the regional reference panel of Japan,” Virol. J., vol. 20, no. 1, p. 93, May 2023, https://doi.org/10.1186/s12985-023-02054-7.
B. Narantuya, “Health index report,” Ulaanbaatar, 2021.
Y. Yang et al., “Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens,” Vaccine, vol. 33, no. 9, pp. 1143–1150, Feb. 2015, https://doi.org/10.1016/j.vaccine.2015.01.031.
S. Usuda et al., “A solid-phase enzyme immunoassay for the common and subtypic determinants of hepatitis B surface antigen with monoclonal antibodies,” J. Immunol. Methods, vol. 87, no. 2, pp. 203–210, Mar. 1986, https://doi.org/10.1016/0022-1759(86)90532-6.
M. Yousefipour, M. Khatami, A. Javidanbardan, S. N. Hosseini, and M. Mehrnia, “Integration of size-exclusion chromatography and ultracentrifugation for purification of recombinant hepatitis B surface antigen: An alternative method for immunoaffinity chromatography,” Prep. Biochem. Biotechnol., vol. 49, no. 2, pp. 158–166, Feb. 2019, https://doi.org/10.1080/10826068.2018.1550658.
M. Krajden, G. McNabb, and M. Petric, “The Laboratory Diagnosis of Hepatitis B Virus,” Can. J. Infect. Dis. Med. Microbiol., vol. 16, no. 2, pp. 65–72, 2005, https://doi.org/10.1155/2005/450574.
Ts. Oyunsuren, “Molecular Genetics Features of HBV, HCV and HAV Spread Among the Mongolian Population,” Ulaanbaatar: Sogoo nuur printing, 2011, pp. 28–29.
Y. Y. Kyaw et al., “Distribution of hepatitis B virus genotypes in the general population of Myanmar via nationwide study,” BMC Infect. Dis., vol. 20, no. 1, p. 552, Dec. 2020, https://doi.org/10.1186/s12879-020-05269-z.
A. Adel Dawood, “Hepatitis B Virus, Genotypes and Subtypes,” in Hepatitis B, IntechOpen, 2022. https://doi.org/10.5772/intechopen.100446.
Ts. Oyunsuren, “Genotypes and mutations of HBV spread in Mongolia,” Mong. J. infected Dis. Res., vol. 4, no. 41, pp. 34–35, 2011.
Downloads
Published
How to Cite
License
Copyright (c) 2023 Damdinbazar Dolgion, Byambajav Bolortuya, Toshiaki Otsuka, Magvansuren Tserendejid, Namjil Erdenebayar, Tsendsuren Oyunsuren, Davaakhuu Gantulga
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright on any research article in the Proceedings of the Institute of Biology is retained by the author(s).
The authors grant the Proceedings of the Institute of Biology license to publish the article and identify itself as the original publisher.
Articles in the Proceedings of the Institute of Biology are Open Access articles published under a Creative Commons Attribution-NonCommercial 4.0 International License - CC BY NC.
This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
